Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 16/20 | 0.60 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.54 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19788059 | 1.00 | FOLH1 (0.60) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20910851 | 0.90 | FOLH1 (0.66) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL24123152 | 0.89 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL9912229 | 0.89 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18253629 | 0.89 | FOLH1 (0.68) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18538620 | 0.87 | FOLH1 (0.48) | FOLH1 | |
| SCHEMBL26758628 | 0.87 | FOLH1 (0.64) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL12118207 | 0.84 | PRMT1 (0.45) | FOLH1 | |
| SCHEMBL19359999 | 0.84 | FOLH1 (0.65) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL19360024 | 0.84 | FOLH1 (0.83) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9877923-B2 | Process for preparing therapeutic nanoparticles | PFIZER INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9872848-B2 | Stable formulations for lyophilizing therapeutic particles | PFIZER INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9835572-B2 | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers | PFIZER INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | PFIZER INC. (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170209374-A1 | METHODS OF CONTROLLING THE MORPHOLOGY OF POLYMERIC NANOPARTICLES | PFIZER (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170189368-A1 | STABLE FORMULATIONS FOR LYOPHILIZING THERAPEUTIC PARTICLES | PFIZER INC. | 2017-07-06 | — | — | US | disclosed |
| US-9579284-B2 | Therapeutic polymeric nanoparticles with mTOR inhibitors and methods of making and using same | PFIZER INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-9579386-B2 | Drug loaded polymeric nanoparticles and methods of making and using same | PFIZER INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20170035694-A1 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING CORTICOSTEROIDS AND METHODS OF MAKING AND USING SAME | PFIZER (US) | 2017-02-09 | — | — | US | disclosed |
| US-20160354320-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | PFIZER INC. | 2016-12-08 | — | — | US | disclosed |
| US-20130108668-A1 | Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same | FIGUEIREDO MARIA (US) | 2013-05-02 | — | — | US | disclosed |
| US-8357401-B2 | Stable formulations for lyophilizing therapeutic particles | BIND BIOSCIENCES, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-8318208-B1 | Drug loaded polymeric nanoparticles and methods of making and using same | BIND BIOSCIENCES, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120288541-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120276162-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | PFIZER INC. | 2012-11-01 | — | — | US | disclosed |
| US-8211473-B2 | Stable formulations for lyophilizing therapeutic particles | BIND BIOSCIENCES, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120140790-A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Termperature or High Molecular Weight Copolymers | PFIZER INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120027820-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PFIZER INC. | 2012-02-02 | — | — | US | disclosed |
| US-20110294717-A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers | PFIZER INC. | 2011-12-01 | — | — | US | disclosed |
| US-20110275704-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PFIZER INC. | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275704-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PRNP, SYNCRIP, LPXN | FOLH1 1774/4885NAALAD2 2971/4885RIMKLA 3673/4885 |
| US-20130108668-A1 | Therapeutic Polymeric Nanoparticles Comprising Epothilone and Methods of Making and Using Same | CD47, EPOR, TTPA | FOLH1 501/4885NAALAD2 4490/4885RIMKLA 2762/4885 |
| US-20120276162-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885 |
| US-20160354320-A1 | DRUG LOADED POLYMERIC NANOPARTICLES AND METHODS OF MAKING AND USING SAME | CD47, LPXN, CD44 | FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885 |
| US-20170189368-A1 | STABLE FORMULATIONS FOR LYOPHILIZING THERAPEUTIC PARTICLES | PRNP, SYNCRIP, LPXN | FOLH1 1774/4885NAALAD2 2971/4885RIMKLA 3673/4885 |
| US-20110294717-A1 | Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers | ACP1, LGALS3, TSG101 | FOLH1 1050/4885NAALAD2 3381/4885RIMKLA 2513/4885 |
| US-20170035694-A1 | THERAPEUTIC POLYMERIC NANOPARTICLES COMPRISING CORTICOSTEROIDS AND METHODS OF MAKING AND USING SAME | CD47, SERPINA6, NR3C1 | FOLH1 1170/4885NAALAD2 3682/4885RIMKLA 3924/4885 |
| US-20120288541-A1 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same | CD47, LPXN, CD44 | FOLH1 173/4885NAALAD2 2614/4885RIMKLA 1707/4885 |
| US-20120027820-A1 | Stable Formulations for Lyophilizing Therapeutic Particles | PRNP, SYNCRIP, LPXN | FOLH1 1774/4885NAALAD2 2971/4885RIMKLA 3673/4885 |
| US-20170209374-A1 | METHODS OF CONTROLLING THE MORPHOLOGY OF POLYMERIC NANOPARTICLES | CLTB, NCL, CLTA | FOLH1 976/4885NAALAD2 3338/4885RIMKLA 1468/4885 |
| US-20170266187-A1 | Pemetrexed Polymeric Nanoparticles And Methods Of Making And Using Same | MTHFD1, TYMP, FPGS | FOLH1 51/4885NAALAD2 3323/4885RIMKLA 482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.